Perrigo’s Loratadine 505(b)(2) NDA Was Properly Submitted, Firm Maintains
This article was originally published in The Tan Sheet
Perrigo chose to file a 505(b)(2) NDA for its generic loratadine 10 mg tablet because at the time it submitted the application, reference listed drug Claritin still was a prescription product, the firm states in recent comments to FDA
You may also be interested in...
Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team
Perrigo introduced two branded products developed in-house at the National Association of Chain Drug Stores Marketplace June 8-10: Dr. Steven Rosenblatt's Ephedra Free Starch Blocker with Phase 2 Starch Neutralizer and Sesame Street Complete Children's Multivitamin Multimineral Supplement
FDA should "send a prompt letter ruling" to Perrigo denying approval of the firm's 505(b)(2) application for 10 mg loratadine tablets, according to an April 15 citizen petition submitted to the agency by Genpharm